Google
CAMP — CAMP4 THERAPEUTICS CORPORATION (Healthcare >> Biotechnology)
CAMP FAQ
What is CAMP's ROE?
CAMP4 THERAPEUTICS CORPORATION reports a Return on Equity (ROE) of -279.27%.
What is CAMP's dividend yield?
CAMP4 THERAPEUTICS CORPORATION offers a dividend yield of 0.00%.
What is CAMP's Deepscope Quality Score?
Deepscope rates CAMP's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CAMP?
Deepscope's AI Timing Score for CAMP is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CAMP belong to?
CAMP4 THERAPEUTICS CORPORATION is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.17
Price
0.19
(4.77%)
Day Change
|
|
|---|
CAMP, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.17 |
| PBV / Sector |
6.69 / 4.48
|
| Earning Per Share | -1.74 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.34 M
GREAT
|
| Average 1W Daily Value |
0.30 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:23:27 |
| Symbol | CAMP |
| Name | CAMP4 THERAPEUTICS CORPORATION |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 51.93 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 206.66 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One Kendall Square, Cambridge, MA, United States, 02139
Phone: 617 651 8867
Website: https://www.camp4tx.com
Sector: Healthcare >> Biotechnology
Description: Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
